SLC22A17

SLC22A17 (BOCT1/NGALR/LCN2R) is an atypical SLC22-family transmembrane protein that functions as a high-capacity, low-affinity iron transporter and as a cell-surface receptor for the iron-carrier lipocalin LCN2, coupling extracellular iron sensing to intracellular iron homeostasis and ferroptotic cell fate [PMID:41397957, PMID:bio_10.1101_2025.06.28.662014]. Unlike canonical SLC22 transporters, it does not transport organic cations or anions such as MPP+ or carnitine; its non-conserved N-terminal domain precludes these activities and instead is organized around a distinctive transmembrane loop atop TM6 (TML6) that gates iron transport independently of LCN2 binding [PMID:21359964, PMID:bio_10.1101_2025.06.28.662014]. Its intrinsically disordered, soluble N-terminal extracellular domain forms a weak fuzzy complex that discriminates apo- from holo-LCN2 (PMID:26635366). At the apical surface of the renal distal nephron it mediates receptor-mediated endocytosis of LCN2 and other filtered metal-binding proteins, and its expression in collecting-duct cells is induced by hypertonicity and vasopressin through NFAT5 and CREB (with Wnt/β-catenin involvement) and repressed by TLR4/LPS, embedding it in an osmotolerance adaptation program (PMID:30404645, PMID:31671521, PMID:37589051). In the brain, SLC22A17 maintains neural stem cell survival and iron balance through an interaction with p62 that restrains the Nrf2/HO-1 pathway; its loss causes neural stem cell apoptosis, iron overload, and oxidative stress (PMID:41397957). Across endothelial, fibroblast, and tumor contexts it promotes iron availability and ferroptosis and modulates barrier integrity and survival signaling: in brain endothelium it drives TNF-α-induced ferroptosis, represses tight-junction gene transcription, and exacerbates blood-brain barrier leakage after ischemia (PMID:38738428, PMID:41386104).

1. 2011 Medium

   Established that SLC22A17, despite belonging to the SLC22 transporter family, does not perform canonical organic cation/anion transport, redefining it as an atypical family member.

   Evidence Heterologous expression in HEK-293 cells with cell-surface verification and radioisotope uptake assays for MPP+, carnitine and other SLC22 substrates

   PMID:21359964

   Open questions at the time

   • Did not identify the true transported substrate
   • Tested only a defined panel of canonical substrates
2. 2015 High

   Resolved how the receptor discriminates LCN2 loading states by showing its disordered N-terminal domain binds apo-LCN2 preferentially in a weak fuzzy complex.

   Evidence Solution-state NMR and biophysical binding assays on the isolated N-terminal domain

   PMID:26635366

   Open questions at the time

   • Weak affinity (~10 µM) indicates the N-terminus alone cannot account for full LCN2 internalization
   • Did not address contribution of the transmembrane region to binding
3. 2015 Medium

   Connected SLC22A17 to neuronal iron-dependent cell death by demonstrating a direct LCN2-BOCT interaction in hippocampal neurons where iron-loaded LCN2 induces Bim and reduces survival.

   Evidence Proximity ligation assay, immunofluorescence, qPCR and survival assays in cultured hippocampal neurons with apo- versus holo-LCN2

   PMID:26004810

   Open questions at the time

   • Did not establish whether iron transport rather than binding drives the death phenotype
   • Single neuronal culture system
4. 2019 Medium

   Defined the transcriptional control of SLC22A17 in collecting-duct cells, placing it within tonicity- and vasopressin-driven osmotolerance signaling.

   Evidence RNAi of Nfat5, pharmacological CREB inhibition, Wnt/β-catenin manipulation and LPS treatment in IMCD and mCCD cells with expression readouts

   PMID:30404645 PMID:31671521

   Open questions at the time

   • Regulatory mechanisms shown in rodent collecting-duct cells only
   • Downstream physiological consequence of induction not directly tested
5. 2023 Medium

   Consolidated SLC22A17 as an apically localized receptor mediating endocytosis of LCN2 and other filtered metal-binding proteins in the distal nephron.

   Evidence Synthesis of fractionation/localization and functional endocytosis studies across multiple labs

   PMID:37589051

   Open questions at the time

   • Review-level synthesis rather than a single primary dataset
   • Molecular determinants of cargo selectivity not defined
6. 2023 Medium

   Positioned Slc22a17 as the effector downstream of LCN2 in suppressing astroglial neurogenesis in disease models.

   Evidence siRNA/AAV knockdown with single-cell transcriptomics and neurogenesis histology in APP/PS1dE9 mice and zebrafish

   PMID:37429840

   Open questions at the time

   • Molecular mechanism linking receptor to neurogenesis suppression not resolved
   • Did not test iron-transport dependence of the phenotype
7. 2024 Medium

   Revealed a pathogenic endothelial role in which SLC22A17 drives ferroptosis and represses tight-junction genes after ischemic stress, compromising the blood-brain barrier.

   Evidence siRNA knockdown and lentiviral overexpression in human brain endothelial cells plus a mouse transient focal ischemia model with permeability and barrier readouts

   PMID:38738428

   Open questions at the time

   • Mechanism of transcriptional repression of tight-junction genes not defined
   • Direct DNA/chromatin interaction not demonstrated
8. 2025 High

   Identified the brain iron-homeostatic mechanism by showing Slc22a17 interacts with p62 to restrain Nrf2/HO-1 activity, with loss causing iron overload, ROS, neural stem cell apoptosis and lethality.

   Evidence Conditional knockout mouse with TurboID proximity labeling, immunoprecipitation, ROS/iron assays and behavioral testing

   PMID:41397957

   Open questions at the time

   • Direct biochemical mechanism by which p62 binding regulates iron efflux not fully resolved
   • Whether transporter activity and p62 interaction are functionally separable untested
9. 2025 High

   Provided the structural and functional basis for iron transport, showing a unique TML6 gating element and demonstrating LCN2-independent high-capacity, low-affinity iron transport.

   Evidence Cryo-EM structure of mouse BOCT1/SLC22A17 with functional transport assays and molecular dynamics (preprint)

   PMID:bio_10.1101_2025.06.28.662014

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Direction and energetics of transport in physiological membranes not fully defined
10. 2025 Medium

    Generalized the pro-ferroptotic, iron-availability function to fibroblasts and tumor cells, linking SLC22A17 to fibroblast activation and oncogenic survival pathways.

    Evidence siRNA/overexpression with ferroptosis and activation markers plus iron chelation in urethral fibroblasts, and siRNA silencing with signaling readouts in TNBC cells

    PMID:41212350 PMID:41386104

    Open questions at the time

    • Whether oncogenic signaling effects are direct or secondary to iron handling unclear
    • Single cell-type studies without in vivo validation
11. 2026 Medium

    Demonstrated a protective holo-LCN2/SLC22A17/Fe3+ axis in transplanted islets, showing receptor-mediated iron import can be anti-apoptotic.

    Evidence Conditioned-medium and co-transplantation experiments with proteomic identification of LCN2 and Fe3+ transport inhibition

    PMID:41964097

    Open questions at the time

    • Context-dependence of pro-survival versus pro-ferroptotic outcomes unresolved
    • Single transplantation model

• How SLC22A17's two activities — iron transport via TML6 and LCN2 receptor/endocytosis function — are coordinated to produce opposite cell-fate outcomes (ferroptosis versus survival) across tissues remains unresolved.
• No unified model reconciling pro-death and pro-survival iron handling
• Determinants of tissue-specific outcome not identified
• Human in vivo physiological/disease validation lacking